WILEX is a biopharmaceutical company developing drugs and diagnostic agents to detect and treat malignant tumors and cancers.
WILEX has raised €24M across 2 funding rounds from 1 investor, most recently a round in Mar 2010. Based in Munich, Germany; founded 2007; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2010-03-01 | Other | €24M | — | View deal → |
| 1999-01-01 | Other | €0 | Earlybird Venture Capital | View deal → |
